EU Novel Food Authorization for CBD: Step-by-Step 2026
US hemp companies seeking to sell CBD products in the European Union must complete the Novel Food authorization process governed by Regulation (EU) 2015/2283. This requires submitting a comprehensive safety dossier to the European Food Safety Authority (EFSA), a process that typically costs between €300,000 and €500,000, takes 18–36 months from pre-submission to authorization, and demands toxicological data that often exceeds what US labs routinely generate.
Why CBD Requires Novel Food Authorization in Europe
The Regulatory Trigger
The European Commission classified CBD extracts and CBD-containing products as "novel foods" in January 2019, updating the Novel Food Catalogue to reflect that cannabis sativa extracts had no significant history of consumption in the EU before May 1997. That cutoff date is the key threshold under Regulation (EU) 2015/2283 — any food or food ingredient without a documented consumption history before it needs authorization.
This applies broadly. Isolates, broad-spectrum extracts, full-spectrum oils, and finished CBD supplements all fall under the regulation. Synthetic CBD follows a separate pathway. Hemp seed oil and hemp seeds themselves are exempt, since their consumption history is well-documented.
What This Means for US Exporters in 2026
Without Novel Food authorization, CBD ingestibles cannot be legally marketed in any EU member state. Several US brands discovered this the hard way between 2020 and 2023, having products pulled from shelves in Germany, the Netherlands, and France. The enforcement landscape has tightened significantly since then.
However, the EU operates a transitional period — more on that below — that creates a narrow window for sales while applications are pending.
The Step-by-Step Authorization Process
Step 1: Pre-Submission Preparation (3–6 Months)
Before you file anything, you need a complete safety dossier. This is the most expensive and time-consuming phase. Your dossier must include:
- Detailed product characterization — full compositional analysis, manufacturing process description, batch-to-batch consistency data, and stability studies
- Toxicological studies — at minimum, a 90-day repeated-dose oral toxicity study in rodents, genotoxicity battery (Ames test, in vitro micronucleus, in vivo micronucleus), and absorption/distribution/metabolism/excretion (ADME) data
- Proposed conditions of use — target population, recommended daily intake, intended food categories
- Nutritional and allergenicity assessments
Most US hemp companies don't have this data sitting in a drawer. Generating a complete toxicology package from scratch typically runs €150,000–€250,000 through a European CRO (contract research organization) and takes 6–12 months of lab work alone.
Step 2: Engage an EU-Based Consultant or Authorized Representative
EFSA requires that non-EU applicants designate an EU-based representative. This isn't optional. Your representative handles correspondence, manages document submissions through the e-submission portal, and serves as the regulatory contact.
Specialized consultancies — firms like Pen & Tec Consulting (Spain), Hylobates Consulting (Italy), and Leatherhead Food Research (UK, for Northern Ireland/GB pathways) — charge between €30,000 and €80,000 for full dossier preparation and project management, depending on complexity.
Choose a firm that has previously submitted CBD-specific Novel Food applications. Generic food-law consultancies often underestimate the cannabinoid-specific requirements EFSA has developed since 2019.
Step 3: Submit the Application
Applications go through the European Commission's e-submission system. Upon receipt, the Commission performs an administrative validity check that takes roughly 30 days. They're checking completeness, not scientific merit.
Key requirements at submission:
- Application form completed in full
- Non-confidential summary (this becomes public)
- Complete safety dossier with all annexes
- Environmental risk assessment (if applicable)
- Payment of applicable fees
If your application passes the validity check, the Commission forwards it to EFSA for scientific evaluation.
Step 4: EFSA Scientific Assessment (12–18 Months)
This is where applications succeed or die. EFSA's Panel on Nutrition, Novel Foods and Food Allergens (NDA Panel) evaluates your dossier against rigorous safety standards.
The evaluation unfolds in stages:
- Initial review and clock start — EFSA has 9 months from receiving a valid application to deliver its scientific opinion, but the clock stops every time they request additional data
- Additional Information Requests (AIRs) — EFSA almost always issues at least one round of questions. For CBD applications specifically, expect questions about long-term exposure modeling, drug interaction potential, and effects on vulnerable populations
- Draft opinion — the NDA Panel circulates an internal draft
- Final scientific opinion — published on EFSA's website with full transparency
The 9-month statutory timeline is misleading. Clock-stops for data requests routinely push the real evaluation period to 14–20 months. As of 2026, no CBD Novel Food application has completed EFSA evaluation — the Food Standards Agency in Great Britain has moved faster with its parallel process, but EFSA's pipeline remains backlogged.
Step 5: Commission Decision and Authorization (2–4 Months)
After EFSA issues a favorable opinion, the European Commission drafts an implementing act to authorize your product. This goes through a comitology procedure involving member state representatives.
If approved, your novel food authorization gets published in the EU's Union List, specifying exact conditions of use — maximum dose, permitted food categories, labeling requirements.
Are US Lab Results Accepted by EFSA?
COAs and Analytical Data
EFSA does not automatically reject US-generated certificates of analysis, but there's a critical caveat. Labs must hold ISO/IEC 17025 accreditation, and analytical methods must align with EU reference standards. Most established US hemp testing labs — think ProVerde, ACS Laboratory — carry 17025 accreditation, so their cannabinoid potency and contaminant panels are generally acceptable.
However, EFSA has flagged insufficiencies in US-standard heavy metals panels, which sometimes test for fewer analytes than EU regulations require. The EU's Regulation (EC) No 1881/2006 sets specific maximum levels for lead, cadmium, mercury, and inorganic arsenic — make sure your COAs cover all four at EU-compliant detection limits.
Toxicological Studies
Here's where it gets more complicated. EFSA requires toxicology studies conducted under OECD Test Guidelines and in compliance with Good Laboratory Practice (GLP) as defined by the OECD. US labs operating under EPA GLP standards (40 CFR Part 160) are broadly compatible, but you must verify mutual recognition.
The safest approach: use a European CRO for your core tox package, or at minimum, have a European toxicologist audit and co-sign US-conducted studies before submission. EFSA reviewers are more comfortable with data from facilities they can inspect.
Selling Under Transitional Enforcement
The Gray Zone That Matters
The EU's transitional measures allow CBD products that were lawfully marketed before January 2019 — or that have a pending Novel Food application — to remain on shelves during the authorization process. This is not a blanket exemption. Each member state enforces differently.
- Germany has been relatively permissive, allowing products linked to pending applications to continue sales
- France lifted its blanket CBD ban after a 2022 Court of Justice of the EU ruling but maintains strict enforcement on novel food compliance for ingestibles
- The Netherlands actively removes non-compliant CBD food products from the market
For US exporters, the strategy is clear: file your Novel Food application as early as possible, then use the pending-application status to access markets through EU distribution partners who understand local enforcement nuances.
Practical Tips for the Transitional Period
- Obtain a validated application reference number from the Commission — this is your proof of pending status
- Work only with EU importers who have experience navigating member-state enforcement variations
- Keep CBD topicals and cosmetics as your primary revenue stream while the food authorization is pending — cosmetics fall under Regulation (EC) No 1223/2009, not Novel Food, and face fewer barriers
- Ensure your products comply with the EU's 0.3% THC limit (recently harmonized across member states) — products exceeding this threshold face narcotics classification regardless of Novel Food status
If you're exploring how different CBD extract types affect your formulation and regulatory strategy, Hurcann's comparison of full spectrum vs. broad spectrum CBD for anxiety breaks down the practical differences.
Common Reasons Applications Get Rejected or Delayed
Data Gaps That Kill Applications
Based on publicly available EFSA correspondence and industry reports through early 2026, the most frequent issues include:
- Insufficient genotoxicity data — submitting only an Ames test without the full battery (in vitro and in vivo micronucleus assays)
- Inadequate ADME characterization — EFSA wants to understand how CBD metabolites behave, not just parent compound pharmacokinetics
- Poorly defined manufacturing processes — vague descriptions of extraction methods trigger immediate requests for clarification
- Batch variability — if your COAs show significant variation in cannabinoid ratios across production batches, EFSA questions whether your safety data applies to the product as actually sold
- Missing exposure assessments — failing to model aggregate CBD exposure across all potential dietary sources
These delays are expensive. Each additional information request can add 3–6 months to your timeline and €20,000–€50,000 in consultant and lab fees.
Budget Reality Check
| Cost Category | Estimated Range (€) |
|---|---|
| Toxicology studies (90-day + genotox battery) | 150,000–250,000 |
| EU regulatory consultant | 30,000–80,000 |
| Stability and analytical testing | 15,000–30,000 |
| Additional information responses | 20,000–50,000 per round |
| Total estimated cost | 300,000–500,000+ |
This isn't a process for companies testing the European market casually. It's a serious capital commitment that makes sense for brands with established US revenue looking to scale internationally. For companies building their domestic foundation first, understanding which CBD strains perform best and reviewing transparent lab results are smarter near-term investments.
Key Takeaways
- CBD ingestibles require Novel Food authorization under EU Regulation 2015/2283 — there is no shortcut or exemption for US-made products
- Realistic timeline is 18–36 months from dossier preparation to authorization, with EFSA clock-stops being the biggest variable
- Budget €300,000–€500,000 for the full process including toxicology, consulting, and additional data requests
- US lab data is conditionally accepted — ISO 17025 accreditation and OECD GLP compliance are non-negotiable
- Transitional enforcement allows pending-application sales in some member states, but enforcement varies significantly by country
- Engage an EU-based consultant with CBD-specific experience early — generic food-law firms underestimate cannabinoid-specific EFSA requirements
These statements have not been evaluated by the FDA. This content is educational and does not constitute legal or regulatory advice. Consult qualified legal counsel before pursuing EU market entry.
Frequently Asked Questions
Q: How long does the EU Novel Food authorization process take for CBD products? A: The statutory EFSA evaluation period is 9 months, but clock-stops for additional data requests extend the real timeline to 14–20 months. Including pre-submission dossier preparation and the Commission's final decision, expect 18–36 months from start to authorization.
Q: What is the Novel Food regulation that applies to CBD in the EU? A: Regulation (EU) 2015/2283 governs novel foods in the European Union. CBD extracts were classified as novel foods in the EU's Novel Food Catalogue in January 2019, meaning any CBD ingestible requires authorization before legal sale.
Q: Does EFSA accept safety studies conducted in US laboratories? A: EFSA accepts US-generated data if studies follow OECD Test Guidelines and the lab holds GLP certification compatible with OECD standards. However, using a European CRO or having a European toxicologist co-sign US studies significantly reduces the risk of data challenges during evaluation.
Q: Can US brands sell CBD in the EU while their Novel Food application is pending? A: Transitional enforcement measures in some member states — notably Germany — permit continued sale of CBD products linked to a valid pending application. Enforcement varies by country, and France and the Netherlands take stricter approaches. Having a validated application reference number is essential.
Q: How much does it cost to get Novel Food authorization for a CBD product? A: Total costs typically range from €300,000 to €500,000 or more. The largest expense is the toxicology package (€150,000–€250,000), followed by EU regulatory consulting (€30,000–€80,000) and responding to EFSA's additional information requests (€20,000–€50,000 per round).
Q: Is the EU Novel Food process different from the UK's CBD authorization pathway? A: Yes. After Brexit, Great Britain operates its own Novel Food process through the Food Standards Agency (FSA), separate from EFSA. The FSA has moved faster on CBD evaluations and maintains its own list of validated applications. Northern Ireland follows EU rules under the Windsor Framework. US exporters targeting both markets need parallel applications.
Q: Are CBD topicals and cosmetics also subject to Novel Food authorization? A: No. CBD cosmetics fall under Regulation (EC) No 1223/2009 (the EU Cosmetics Regulation), not the Novel Food framework. This is why many US brands prioritize topical products as their initial EU market entry while their Novel Food application for ingestibles is pending.
About the Author — Hurcann Editorial Team The Hurcann team has spent years working directly with licensed hemp cultivators, extraction labs, and independent testing facilities across the United States. Our content is reviewed against current COA data, state hemp regulations, and peer-reviewed cannabinoid research before publication. We are not medical professionals and nothing here constitutes medical advice — always consult a healthcare provider before adding hemp products to your wellness routine.